Xbrane Biopharma AB (FRA:7XB0) Total Liabilities: €9.47 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7XB0 Xbrane Biopharma AB FRA:7XB0
71 GF Score
Price €0.77
GF Value €0.49
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB Total Liabilities?

Xbrane Biopharma AB FRA:7XB0 -1.28% 71 Total Liabilities is €9.47 Mil as of Jun. 2026. GuruFocus rates FRA:7XB0 with a GF Score™ of 71/100 and a GF Value™ of €0.49. The stock has 6 warning signs investors should review.

Xbrane Biopharma AB's Total Liabilities for the quarter that ended in Jun. 2026 was €9.47 Mil.

Xbrane Biopharma AB's quarterly Total Liabilities increased from Dec. 2025 (€10.20 Mil) to Mar. 2026 (€11.20 Mil) but then declined from Mar. 2026 (€11.20 Mil) to Jun. 2026 (€9.47 Mil).

Xbrane Biopharma AB's annual Total Liabilities increased from Dec. 2023 (€43.11 Mil) to Dec. 2024 (€55.11 Mil) but then declined from Dec. 2024 (€55.11 Mil) to Dec. 2025 (€10.20 Mil).

Xbrane Biopharma AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Xbrane Biopharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB Total Liabilities Chart

Xbrane Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.99 24.16 43.11 55.11 10.20

Xbrane Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.70 10.40 10.20 11.20 9.47
FRA:7XB0
71GF Score
Xbrane Biopharma AB FRA:7XB0
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xbrane Biopharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Xbrane Biopharma AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.839+(5.358+-8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=10.20

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=61.717-51.52
=10.20

Xbrane Biopharma AB's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.194+(0.271+-9.9920072216264E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.47

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=58.619-49.153
=9.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €9.47 Mil mean?
Xbrane Biopharma AB (FRA:7XB0) has a Total Liabilities of €9.47 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's Total Liabilities too high?
Xbrane Biopharma AB's current Total Liabilities is €9.47 Mil. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's Total Liabilities compare to VRTX and REGN?
Xbrane Biopharma AB's Total Liabilities of €9.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current Total Liabilities is €9.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Xbrane Biopharma AB (FRA:7XB0) has a current Total Liabilities of €9.47 Mil. The stock's GF Value™ is €0.49, compared to a current price of €0.77 — trading 57.6% above its estimated fair value. The current Total Liabilities is €9.47 Mil. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Xbrane Biopharma AB (FRA:7XB0), the current Total Liabilities is €9.47 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (FRA:7XB0) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of €0.77 is trading 57.6% above its estimated GF Value™ of €0.49.

Key valuation signals for FRA:7XB0:

  • Total Liabilities: €9.47 Mil
  • GF Value™: €0.49 vs. price of €0.77 (57.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xbrane Biopharma AB Business Description

Other Exchanges XBRANE:Sweden
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score

Get the complete analysis for FRA:7XB0

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€0.49
GF Value